SCHEMBL29807013

SCHEMBL29807013

COC(=O)C1C(=O)CC[C@H]1C

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
CYP1A2 P05177 1/20 0.43
HIF1A Q16665 1/20 0.43
BRD4 O60885 1/20 0.38
TLR4 O00206 2/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.34
TSHR P16473 4/20 0.34
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
KDM4E B2RXH2 2/20 0.34
HTT P42858 2/20 0.34
HSD17B10 Q99714 1/20 0.34
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RECQL P46063 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9122696 1.00 ALDH1A1 (0.46) ALDH1A1CYP1A2HIF1ABRD4TLR4
SCHEMBL19104463 0.89 ALDH1A1 (0.44) ALDH1A1CYP1A2HIF1ABRD4SMN1; SMN2
SCHEMBL29127898 0.89 ALDH1A1 (0.44) ALDH1A1CYP1A2HIF1ABRD4SMN1; SMN2
SCHEMBL12847556 0.82 TLR4 (0.31) ALDH1A1TLR4MAPK1
SCHEMBL11014967 0.81 MAPK1 (0.50) ALDH1A1KMT2AMAPK1
SCHEMBL3301366 0.81 CYP1A2 (0.46) ALDH1A1CYP1A2HIF1ABRD4KMT2A
SCHEMBL8020201 0.80 CYP1A2 (0.43) ALDH1A1CYP1A2HIF1ABRD4SMN1; SMN2
SCHEMBL7718731 0.80 CYP1A2 (0.43) ALDH1A1CYP1A2HIF1ABRD4SMN1; SMN2
SCHEMBL8020205 0.80 CYP1A2 (0.43) ALDH1A1CYP1A2HIF1ABRD4SMN1; SMN2
SCHEMBL680912 0.79 ALDH1A1 (0.41) ALDH1A1CYP1A2TLR4POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150293-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS VERNALIS (R&D) LTD (GB) 2024-05-09 US disclosed
EP-4277892-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS Les Laboratoires Servier (FR) 2023-11-22 EP disclosed
CN-116940552-A Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors 法国施维雅药厂 2023-10-24 CN disclosed
WO-2022152705-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS LES LABORATOIRES SERVIER (FR) 2022-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150293-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BAX, BCL2A1 ALDH1A1 1439/4885CYP1A2 888/4885HIF1A 1937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.